When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. Zoetis stock just cleared that benchmark with an upgrade from 70 to 81.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of other stocks on the major indexes.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating as they begin their biggest runs.
See How IBD Helps You Make More Money In Stocks
Is Zoetis Stock A Buy?
Zoetis stock is within a buying range after climbing above a 187.82 buy point in a cup without handle. The proper buying range extends to 5% above the initial entry. Once a stock hits that benchmark, it's best to hold off investing and wait for it to set up another buying opportunity.
Earnings grew 18% last quarter, up from -1% in the prior report. Revenue also increased, from 1% to 6%.
Zoetis stock earns the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. Zoetis and Novartis ADR are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
